Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Eukaryotic translation initiation factor 3 subunit B (EIF3B)
- Target
- EIF3B
- Molecular classification
- Translation initiation factor, Scaffold protein, Non-canonical RNA recognition motif-containing protein
01
Overview
Eukaryotic translation initiation factor 3 subunit B (eIF3b) is a highly conserved structural and regulatory element of the multi-protein eIF3 complex, which orchestrates the initiation phase of eukaryotic protein synthesis by scaffolding and stabilizing the assembly of the 43S preinitiation complex. It mediates recruitment of the 40S ribosomal subunit to mRNA and enforces accurate start codon selection, functioning through a non-canonical RNA recognition motif involved in protein-protein interactions. eIF3b is central to translation regulation, cell growth, and is implicated in oncogenic processes; its activity is modulated by post-translational modifications such as phosphorylation, making it a potential therapeutic target and biomarker in cancer
- Other names
- eIF3bEIF3BEIF3S9eIF3s9Prt1 homologPRT1hPrt1eIF-3-etaeIF3 p110eIF3 p116protein synthesis 1EIF3-ETAEIF3-P110EIF3-P116
02
Mechanism of action
Inhibition or activation of kinases/phosphatases affecting eIF3b phosphorylation state, thus modulating translation initiation and tumor cell growth
03
Biological functions
Protein translation initiationRecruitment and scaffolding of the 43S preinitiation complexmRNA recruitment and scanningInteraction with ribosomal subunitsRegulation of cell growthControl of start codon recognition
04
Disease associations
Cancer (oncogenesis, cell proliferation)Potential roles in other proliferative or metabolic disorders (due to central protein synthesis regulation)
05
Safety considerations
As a core factor in general protein synthesis, inhibiting eIF3b risks toxicity through suppression of global translation, particularly in proliferative normal cellsPotential off-target effects and loss of cell viability
06
Interacting drugs
No clinically approved drugs now directly target eIF3b; experimental modulation may occur via upstream kinase/phosphatase inhibitors regulating eIF3b phosphorylation
07
Biomarkers
eIF3b expression or phosphorylation status can serve as a biomarker for cancer prognosis or treatment response
Beyond the preview
Go deeper on Eukaryotic translation initiation factor 3 subunit B (EIF3B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eukaryotic translation initiation factor 3 subunit B (EIF3B).